Marapharm Ventures Inc. Enters Into An Agreement-In-Principle Expanding Its Washington State Operations With Sun-Grown Production
KELOWNA, BC, May 29, 2018 /CNW/ - Marapharm Ventures Inc. (CSE: MDM) (OTCQX: MRPHF) (FSE: 2M0) ("Marapharm" or the "Company") announced by press release on March 26, 2018, and April 18, 2018, respectively, that the Company had entered into a Letter of Intent and Definitive Agreements to expand the Company's Washington State operations. The Company is very pleased to announce that it has closed the foregoing transactions and acquired certain operational assets, land and water rights related to two licensed cannabis producers and processors (the "Licensees") operating in Tonasket, Washington (the "Property").
Just South of the Canadian border in Central Washington, Tonasket is home to some of the world's most productive orchards. This ideal climate sees approximately 300 days of sunshine a year providing a cannabis grow season that can last approximately 164 days.
The sun-grown season is currently underway in Tonasket. Sun-grown cannabis can be as terpene-rich as indoor, demonstrating the unique aroma and flavor profiles imparted by the culmination of various factors including growing location, soil, elevation and climate.
To take advantage of the sun-grown season, Marapharm is currently funding the preparation of the Property for this summer's cultivation and fall harvest. All above-ground irrigation has been installed and growing areas constructed for both Licensees. The Licensees have also secured all necessary operating permits and approvals needed to bring cannabis plants on site starting the last week of May.
In addition, the Licensees have secured the services of Mr. Ian Dykstra to manage the day-to-day operations of the Licensees. Mr. Dykstra is a master grower who has extensive cannabis growing experience and owns his own cannabis production license. He recently won "Best Light Dep Flower - THC" at Sun Cup 2018. To date, Mr. Dykstra has ensured preparations at the Property are under budget and on schedule.
The Licensees will cultivate up to 40,000 sq. ft. of cannabis plant canopy. Marapharm anticipates to be processing this sun-grown cannabis product at the licenced facility located in Lynden, Washington.
"We are excited to assist our Washington partners commence planting and growing in Tonasket. For the "cannassieur," it is the experience of seeking unique nuances of flavor imparted by the earth which can be detected in sun-grown cannabis". Linda Sampson, CEO
ABOUT MARAPHARM VENTURES INC.
Marapharm is a publicly traded company investing in the medical and recreational cannabis space, since 2014. Marapharm has rapidly expanded to include having cultivation, production and dispensary locations in the key North American states of Washington, Nevada, and California, and are seeking expansion opportunities worldwide.
SOCIAL MEDIA:
Facebook: facebook.com/marapharm
Twitter: twitter.com/marapharm
Web Program: marapharm.tv
STOCK EXCHANGES:
Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQX, and in Europe, ticker symbol 2M0 on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L & S, Quotnx, Dusseldorf, Munich, and Berlin.
Neither the CSE, the FSE nor the OTCQX® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQX® accepts responsibility for the adequacy or accuracy of this release.
MARIJUANA INDUSTRY INVOLVEMENT:
Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is rightly required by regulators and complying with applicable licensing requirements and the regulatory framework enacted by the applicable state in which they operate.
Marapharm owns marijuana licenses in California and Nevada. Marijuana is legal in each state however marijuana remains illegal under US federal law and the approach to enforcement of US federal law against marijuana is subject to change. Shareholders and investors need to be aware that adverse enforcement actions could affect their investments and that Marapharm's ability to access private and public capital could be affected and or could not be available to support continuing operations. Marapharm's business is conducted in a manner consistent with state law and is in compliance with licensing requirements.
Copies of licenses are posted on Marapharm's website. Marapharm has internal compliance procedures in place and has compliance focused attorneys engaged in jurisdictions to monitor changes in laws for compliance with US federal and state law on an ongoing basis. These law firms inform any necessary changes to our policies and procedures for compliance in Canada and the US.
FORWARD - LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward- looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward- looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.
SOURCE Marapharm Ventures Inc.
www.marapharm.com or Linda Sampson, CEO 778-583-4476, email [email protected]
Share this article